Equities Analysts Offer Predictions for KRMD FY2024 Earnings

KORU Medical Systems, Inc. (NASDAQ:KRMD) – Investment analysts at B. Riley upped their FY2024 earnings estimates for shares of KORU Medical Systems in a research note issued on Tuesday, January 14th. B. Riley analyst K. Bauser now anticipates that the company will post earnings of ($0.13) per share for the year, up from their prior estimate of ($0.14). The consensus estimate for KORU Medical Systems’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for KORU Medical Systems’ Q4 2024 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.09) EPS.

Several other equities analysts have also commented on the company. Lake Street Capital increased their price objective on KORU Medical Systems from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday. Piper Sandler increased their price target on shares of KORU Medical Systems from $3.00 to $3.50 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Canaccord Genuity Group boosted their price objective on shares of KORU Medical Systems from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Finally, Craig Hallum upped their price objective on shares of KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Friday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $4.50.

KORU Medical Systems Trading Up 2.3 %

NASDAQ KRMD opened at $4.09 on Thursday. The company has a quick ratio of 2.37, a current ratio of 2.99 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $3.80 and its two-hundred day simple moving average is $2.96. KORU Medical Systems has a twelve month low of $1.98 and a twelve month high of $4.60. The company has a market capitalization of $187.47 million, a price-to-earnings ratio of -16.36 and a beta of 0.45.

Hedge Funds Weigh In On KORU Medical Systems

A number of large investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of KORU Medical Systems in the second quarter worth approximately $107,000. Meros Investment Management LP boosted its position in KORU Medical Systems by 20.7% during the 2nd quarter. Meros Investment Management LP now owns 804,380 shares of the company’s stock valued at $2,132,000 after buying an additional 137,918 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in KORU Medical Systems by 77.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 61,412 shares of the company’s stock worth $168,000 after acquiring an additional 26,860 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of KORU Medical Systems in the third quarter valued at about $34,000. Finally, Geode Capital Management LLC raised its stake in shares of KORU Medical Systems by 6.5% during the third quarter. Geode Capital Management LLC now owns 462,128 shares of the company’s stock valued at $1,262,000 after acquiring an additional 28,323 shares during the last quarter. 58.60% of the stock is owned by hedge funds and other institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.